143 related articles for article (PubMed ID: 15638859)
1. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
Ferrara F; Palmieri S; De Simone M; Sagristani M; Viola A; Pocali B; Fasanaro A; Mele G
Br J Haematol; 2005 Jan; 128(2):234-41. PubMed ID: 15638859
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
[TBL] [Abstract][Full Text] [Related]
5. High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
Ferrara F; Annunziata M; Schiavone EM; Copia C; De Simone M; Pollio F; Palmieri S; Viola A; Russo C; Mele G
Hematol J; 2001; 2(4):214-9. PubMed ID: 11920252
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Jerjis S; Roovers E; Muus P; Schaap N; de Witte T
Bone Marrow Transplant; 1998 Jul; 22(1):13-9. PubMed ID: 9678790
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients.
Isidori A; Bonifazi F; Visani G; Gherlinzoni F; Baccarani M; Lemoli RM
Haematologica; 2005 Jan; 90(1):139-41. PubMed ID: 15642686
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission.
Kim HJ; Min WS; Eom KS; Park SJ; Park YH; Kim DW; Lee JW; Park CW; Kim CC
Bone Marrow Transplant; 2004 Aug; 34(3):215-20. PubMed ID: 15170169
[TBL] [Abstract][Full Text] [Related]
10. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
13. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
[TBL] [Abstract][Full Text] [Related]
15. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
[TBL] [Abstract][Full Text] [Related]
16. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
[TBL] [Abstract][Full Text] [Related]
17. High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
Meloni G; Capria S; Trasarti S; Ferrazza G; Micozzi A; Petrucci MT; Simone F; Trisolini SM; Mandelli F
Bone Marrow Transplant; 2000 Nov; 26(10):1045-9. PubMed ID: 11108301
[TBL] [Abstract][Full Text] [Related]
18. High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?
Hong M; Miao KR; Zhang R; Lu H; Liu P; Xu W; Chen LJ; Zhang SJ; Wu HX; Qiu HX; Li JY; Qian SX
Med Oncol; 2014 Jun; 31(6):980. PubMed ID: 24802329
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
20. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
